Introduction
Mesenchymal stem cells (MSCs) are a group of adult stem cells derived from the mesoderm, characterized by their self-renewal, proliferation and differentiation capacity. MSCs can be isolated from a variety of different tissues, including bone marrow, adipose tissue and brain tissue (1–3). Bone marrow-derived MSCs (BM-MSCs) are easily isolated and amplified, and can be induced to differentiate into adipocytes, osteocytes, chondrocytes and neuron-like cells (4). Basic and clinical applications of BM-MSCs have attracted considerable attention, particularly in tissue repair, cell transplantation and anticancer therapy. Furthermore, BM-MSCs have immunoregulatory capacity in a variety of immune cells including T lymphocytes, NK cells and dendritic cells (5,6). Moreover, BM-MSCs also have the migratory ability towards tumor lesions including gliomas (7). The data from in vitro experiments confirmed that BM-MSCs had the capacity to migrate towards gliomas, and the migratory activity was strengthened in a dose-dependent manner with increasing numbers of glioma cells (8). Previous reports also showed that BM-MSCs could migrate towards gliomas through blood tumor barrier in vivo(9,10).
Due to the aggressive and invasive growth patterns, gliomas are difficult to be completely cured by surgical resection and adjuvant chemo- and radiotherapy. In recent years, with the enhanced understanding of glioma pathogenesis, targeted gene therapy has been the hotspot in the research of glioma treatments. Finding appropriate vectors for targeted gene therapy against gliomas is of great importance. On the basis of their migrating capacity towards gliomas, BM-MSCs have been applied as carriers of targeted therapy against gliomas. Moreover, previous studies indicated that genetically modified BM-MSCs still displayed the tropism towards gliomas without changing their original phenotypes or abnormal differentiation (11–13). However, the mechanisms in the migration of BM-MSCs towards gliomas have yet to be fully elucidated. Understanding the related mechanisms will aid in improving the efficiency of glioma targeted therapy based on BM-MSCs.
As a member of the platelet-derived growth factor (PDGF) family, platelet-derived growth factor BB (PDGFBB) is a homodimer of encoded product of proto-oncogene c-sis. The expression of PDGFBB is closely related to the angiogenesis and invasiveness of glioma (14). Furthermore, previous reports showed that PDGFBB not only acted as a potent mitogen for cells of mesenchymal origin, but also attracted the migration of BM-MSCs (15–17). There are two receptors of PDGF (PDGFR), PDGFR α and PDGFR β. PDGFBB binds to both PDGF receptors. Moreover, PDGFBB and PDGFR β are overexpressed in human gliomas and are responsible for recruiting peri-endothelial cells to vessels (14). It has been confirmed that PDGFBB plays a crucial role in the migration of BM-MSCs towards glioma (16,17). The migration of BM-MSCs toward gliomas might be due to the interaction between the cytokines and chemokines secreted by glioma cells and the receptors expressed on BM-MSCs. However, studies on the adhesion molecules expressed on BM-MSCs are limited.
Vascular cell adhesion molecule-1 (VCAM-1) is an important cell surface adhesion molecule and is expressed by various cells. The interaction between VCAM-1 and its receptor integrin α4β1 plays a critical role in the transmigration of T lymphoblasts and leukocytes across the blood-brain barrier (BBB) under pathophysiological conditions (18,19). It has been reported that VCAM-1 is expressed exactly on the surface of BM-MSCs (20). In addition, VCAM-1 also plays important roles in the adhesion of BM-MSCs to cardiac microvascular endothelium and glioma cells (20,21). Therefore, it is necessary to investigate whether PDGFBB promotes BM-MSC migration by upregulating the VCAM-1 expression, which may be one mechanism in the migration of BM-MSCs towards gliomas. The binding of PDGFBB and its receptors results in the activation of several intracellular downstream signaling mediators, including phosphoinositide-3-kinase (PI3K), p38 mitogen-activated protein kinase (p38MAPK), mitogen-activated protein kinase kinase (MEK), c-Jun N-terminal kinase (JNK) and nuclear factor-κB (NF-κB) (22–26). Thus, it is necessary to identify whether these signal molecules participate in signal transduction in the migration and VCAM-1 expression regulation induced by PDGFBB.
Based on these reports, it is reasonable to hypothesize that PDGFBB promotes the migration of BM-MSCs by upregulating their VCAM-1 expression, which may be a key mechanism in the tropism of BM-MSCs towards gliomas. The aim of the present study was to investigate the role of VCAM-1 in the PDGFBB-induced migration of BM-MSCs, to elucidate the effects of PDGFBB on VCAM-1 expression of BM-MSCs and to ascertain the roles of PI3K, p38MAPK, MEK, JNK and NF-κB in this process.
Materials and methods
Animals
Four- to six-week-old healthy female SD rats, weighing 80–100 g, were used for the isolation and culture of BM-MSCs. The rats were provided by the Laboratory Animal Center of China Medical University. All animal experiments were carried out in accordance with the National Institute of Health Guide for the Care and Use of Laboratory Animals and were authorized by the Animal Care and Use Committee of China Medical University.
Isolation and culture of rat BM-MSCs
BM-MSCs were isolated by the method of whole bone marrow adherent culture as previously described (10). In brief, after being anesthetized with 10% chloral hydrate (3.5 ml/kg, intraperitoneal injection), the rats were sacrificed by cervical dislocation. The bone marrow was then flushed out from bilateral femurs and tibias under sterile conditions using low glucose Dulbecco’s Modified Eagle’s Medium (L-DMEM; Gibco) supplemented with 10% fetal bovine serum (FBS; Gibco). The cell suspension was seeded into 75 cm2 flask, and cultured at 37°C in the presence of 5% CO2. After 48 h, the culture media were changed to discard non-adherent cells. Subsequently, media were changed every 72 h. Twelve-fourteen days later, the cells grew to 90% confluence. After digesting with 0.25% trypsin, the cells were passaged in accordance with the ration of 1:2. Then, 5–7 days later, the cells were passaged again. The cells of passage 3 were used for the following experiments.
Flow cytometric assay
Third-passage BM-MSCs were harvested and centrifuged at 1,000 rpm for 5 min. The cells were resuspended in PBS at a concentration of 1×106 cells/ml and immunolabeled with FITC-labeled anti-CD34, CD45, CD73, CD90 and CD105 antibodies (Santa Cruz Biotechnology, Santa Cruz, CA, USA) at room temperature for 30 min in the dark. The cells were then washed with PBS three times. Ten thousand events per sample were acquired using a FACScan flow cytometer (Becton-Dickinson, San Jose, CA, USA).
Preparation of glioma conditioned medium (CM) and enzyme linked immunosorbent assay (ELISA)
C6 and U87 glioma cells (American Type Culture Collection, Rockville, MD, USA) were cultured in L-DMEM supplemented with 10% FBS, separately. When the cells grew to 70–80% confluence, C6 and U87 cells were collected and resuspended in serum-free L-DMEM. The CM of C6 and U87 glioma cells was prepared according to the previously described method (27). In brief, 1×106 C6 or U87 cells were plated into 75 cm2 flask and cultured for 24 h using serum-free medium. The culture supernatants of C6 and U87 cells were then collected and centrifuged at 2,000 rpm for 10 min. Equal amounts of CM were stored at −20°C until use. Serum-free L-DMEM was used as a negative control. The PDGFBB released by C6 and U87 glioma cells was detected with a specific PDGFBB ELISA kit (Beijing Dingguo Biotechnology Co., Ltd., Beijing, China) according to the manufacturer’s recommendation.
In vitro migration assay
The migration of BM-MSCs was evaluated in 24-well plates with Transwell inserts of 8-μm pore size (Corning Costar). To evaluate the role of VCAM-1 in the PDGFBB-induced migration of BM-MSCs, serum-free L-DMEM containing 50 μg/l PDGFBB was placed in the lower chambers. BM-MSCs were trypsinized and resuspended in serum-free L-DMEM at the density of 5×105/ml, and 200 μl of BM-MSC suspension was added into the upper chambers. Serum-free L-DMEM served as a negative control. The VCAM-1-neutralizing antibody (MMS-141P; Covance) was added in the suspension of BMSC at a concentration of 10 μg/ml to neutralized VCAM-1 bioactivity. After co-culturing for 36 h, the inserts were taken out, and cells that remained on the upper surface of the filters were removed carefully with a cotton wool swab. The cells migrating to the lower surface were washed with phosphate-buffered saline (PBS) and fixed with methanol and glacial acetic acid (mixed at 3:1) for 30 min at room temperature and stained in Giemsa stain for 15 min. The average number of migrating cells was counted in six random high-power fields (original magnification, ×200).
Immunofluorescence
BM-MSCs were collected and seeded onto 1.5% gelatin-coated coverslips. When they grew to 80% confluence, BM-MSCs were incubated with serum-free L-DMEM containing 20 ng/ml PDGFBB with or without an anti-PDGFBB antibody (Abcam, 50 μg/ml) for 24 h, respectively. For immunofluorescence assays, after fixing with 4% paraformaldehyde, BM-MSCs were incubated with the VCAM-1 polyclonal rabbit anti-rat antibody at 4°C overnight. Then, goat anti-rabbit rhodamine-labeled fluorescent secondary antibodies (diluted at 1:5,000; Santa Cruz Biotechnology) were added for subsequent visualization. The nuclei were stained with DAPI at a dilution of 1:500. Images were captured with an Olympus BX60 Upright Fluorescence microscope with appropriate filters and objectives, using identical acquisition parameters per experiment.
Reverse transcription (RT)-PCR
For analysis of the effect of PDGFBB on the VCAM-1 expression of BM-MSCs, the cells were incubated with serum-free L-DMEM containing 0, 10, 20, 50 and 100 ng/ml PDGFBB for 24 h, separately. Furthermore, for analyzing the related signal transduction mechanism in PDGFBB-induced VCAM-1 expression changes of BM-MSCs, PI3K inhibitor LY294002 (30 μM; Cell Signaling Technology), p38MAPK inhibitor SB203580 (10 μM; Enzo Life Sciences), MEK inhibitor PD98059 (10 μM; Enzo Life Sciences), JNK inhibitor SP600125 (10 μM; Enzo Life Sciences) and NF-κB inhibitor BAY11-7082 (5 μM; Enzo Life Sciences) were used to treat BM-MSCs for 30 min before, and for the duration of PDGFBB incubation, respectively. Serum-free L-DMEM was applied as a negative control.
Total RNA was extracted with TRIzol (Invitrogen) in accordance with the manufacturer’s instructions. Reverse transcription reaction of cDNA was performed using Takara’s PCR kit (AMV) ver 3.0. The sequences of VCAM-1 primers were 5′-ACACCTCCCCCAAGAATACAG-3′ (forward) and 5′-GCTCATCCTCAACACCCACAG-3′ (reverse), and the amplified fragment length was 477 bp (28). β-actin was applied as internal control. The sequences of β-actin primers were 5′-CACCCGCGAGTACAACCTTC-3′ (forward) and 5′-CCCATACCCACCATCACACC-3′ (reverse). PCR reaction was carried out with denaturing at 94°C for 30 sec, annealing at 62°C for 30 sec, extending at 72°C for 1 min, and 32 cycles for VCAM-1 and 29 cycles for β-actin. The PCR product was purified using 1% agarose gel electrophoresis containing ethidium bromide, and then light in the ultraviolet was emitted, and the ratio of the integral optical density (IDV) of the VCAM-1 and β-actin gene was calculated.
Western blotting
The incubation of BM-MSCs was performed as described in RT-PCR. The cells from each group were washed three times with ice-cold PBS to stop the stimulation. Then, the cells were gathered with cell scraper and total protein was extracted in ice-cold lysis buffer containing 50 mM Tris (pH 7.4), 1% Triton X-100, 150 mM NaCl, 0.1% sodium dodecyl sulfate (SDS), 1% sodium deoxycholate, sodium fluoride, sodium orthovanadate, and EDTA (Beyotime Institute of Biotechnology) for 30 min. The samples were then sonicated with an ultrasonic crusher, and centrifuged at 14,000 × g for 5 min at 4°C. The supernatant was collected as the soluble fraction and transferred to a new tube. The protein concentration of supernatant samples was measured with BCA method (BCA protein assay kit; Beyotime Institute of Biotechnology), with bovine serum albumin used as a standard. The same amount of protein lysates (25 μg/lane) was fractioned by 10% SDS-polyacrylamide gel electrophoresis and treated for immunoblotting with anti-VCAM-1 antibodies (diluted at 1:100; Santa Cruz Biotechnology) and anti-β-actin antibody (diluted at 1:2,000; Santa Cruz Biotechnology), respectively. All the protein bands were scanned using Chemi Imager 5500 V2.03 software, and the IDV were calculated by computerized image analysis system (Fluor Chen 2.0) and normalized with that of β-actin.
Statistical analysis
Experiments were repeated in at least triplicate replications. All results are presented as means ± SD. Differences between two groups were analyzed by using a Student’s t-test. One-way analysis of variance test followed by Dunnett’s post-test were performed to compare differences among multiple groups. P<0.05 was considered to indicate a statistically significant result.
Results
Morphology and immunophenotype characterization of BM-MSCs in vitro
Cells isolated from rat bone marrow and seeded into L-DMEM formed typical fibroblastoid colonies after ~5 days and reached 80–90% confluence within 12–14 days. After passage 3, BM-MSCs were grown into a homogenous monolayer of adherent spindle-shaped cells (Fig. 1), which is consistent with the literature (9).
Before the following experiments were performed, flow cytometric assays were carried out to identify the immunophenotype of isolated BM-MSCs. The results demonstrated that rat BM-MSCs were negative for CD34 (0.69%) and CD45 (1.32%), and positive for CD90 (99.98%), CD73 (96.37%) and CD105 (98.59%) (Fig. 2). These results showed that the isolated cells were in line with the definition of MSCs (29,30).
Secretory PDGFBB is detected in the CM of glioma cells
Platelet-derived growth factor is a 30-kDa protein consisting of disulfide-bonded dimers of A-, B-, C- or D-chains, which has important functions in development and is required for gliogenesis such as oligodendrocyte differentiation (31). PDGF is also expressed in various glioma cell lines and functions in the gliomagenesis and tumoral angiogenesis (14,31,32). Previous studies have demonstrated that PDGFBB contributes to the migration of BM-MSCs towards gliomas (16,17). On the basis of these reports, the secretion of PDGFBB in the CM of C6 and U87 cells was assayed with the ELISA method. The data showed that PDGFBB was detected in the CM of C6 and U87 cells, and the average concentrations of secretory PDGFBB for C6 and U87 cells were 6.11 and 7.75 ng/l, respectively.
VCAM-1 is a key factor associated with the PDGFBB-induced migration of BM-MSCs
The mechanisms related to the migration of BM-MSCs towards glioma remain poorly understood. As an important adhesion molecule, VCAM-1 plays a key role in mediating the adhesion and migration of leukocytes and vascular smooth muscle cells (33,34). Our previous study also revealed that VCAM-1 was upregulated and functioned as a crucial adhesion molecule in the glioma-induced tropism of BM-MSCs (20). In order to clarify the relationship between VCAM-1 and PDGFBB in the migration of BM-MSCs, a blocking antibody against VCAM-1 was employed in the migration assay in vitro. The results revealed that the number of migrating BM-MSCs induced by PDGFBB was significantly reduced with the employment of anti-VCAM-1 antibody compared with the control group (Fig. 3), indicating that VCAM-1 is involved in mediating the PDGFBB-induced migration of BM-MSCs.
PDGFBB promotes the expression of VCAM-1 in BM-MSCs in immunofluorescence
Previous studies revealed that VCAM-1 contributed to the migration of BM-MSCs induced by PDGFBB. Therefore, further studies were necessary to clarify the impact of PDGFBB on the VCAM-1 expression. The expression of VCAM-1 was first examined by immunofluorescence. The results are shown in Fig. 4. Under the treatment of PDGFBB at the concentration of 20 ng/ml, VCAM-1 expression was clearly promoted compared with the control group (Fig. 4C). The antibody against PDGFBB significantly attenuated the promoted expression of VCAM-1 (Fig. 4D).
PDGFBB upregulates the expression levels of VCAM-1 mRNA and protein
RT-PCR and western blot analysis were performed to evaluate the changes of mRNA and protein expression levels under conditions of various concentrations of PDGFBB. BM-MSCs were treated with PDGFBB at concentrations of 10, 20, 50 and 100 ng/ml. The results demonstrated that 20, 50 and 100 ng/ml significantly elevated the VCAM-1 expression of BM-MSCs compared with 0 ng/ml groups (P<0.05) (Fig. 5A and C). For the 10 ng/ml group, the VCAM-1 expression of BM-MSCs was also increased, although it was not statistically significant (P>0.05) (Fig. 5B and D). PDGFBB of 50 ng/ml displayed the maximum promoting effect on VCAM-1 expression. Based on these observations, 50 ng/ml was applied in the following investigation of downstream signal transduction pathways activated by PDGFBB.
Blocking of PI3K, p38MAPK and NF-κB inhibits the PDGFBB-induced upregulation of VCAM-1
To examine the related intracellular signal pathway in the promotion of VCAM-1 expression induced by PDGFBB, LY294002, SB203580, PD98059, SP600125 and BAY11-7082 were employed to neutralize the functions of PI3K, p38MAPK, MEK, JNK and NF-κB. BM-MSCs were cultured in serum-free L-DMEM supplemented with PDGFBB of 50 ng/ml with or without LY294002, SB203580, PD98059, SP600125 and BAY11-7082 for 24 h. As shown in Fig. 5, LY294002, SB203580, and BAY11-7082 significantly reduced VCAM-1 expression of BM-MSCs compared with the 50 ng/ml group (P<0.05; Fig. 6). By contrast, there was no significant alteration of VCAM-1 expression under the co-incubation of PD98059 and SP600125 with PDGFBB. These results indicate that PI3K, p38MAPK and NF-κB participate in the regulation of PDGFBB-induced VCAM-1 expression of BM-MSCs, while MEK and JNK are not involved in the process.
Inhibition of PI3K and NF-κB attenuates the PDGFBB-induced migration of BM-MSCs
To investigate the related mechanism of PDGFBB-induced BM-MSC migration, we also utilized LY294002, PD98059, SP600125 and BAY11-7082 in the in vitro migration assay. The data presented in Fig. 5 show that the addition of LY294002 or BAY11-7082 notably reduced the chemotactic effect of PDGFBB. By contrast, SP600125 and BAY11-7082 had no obvious effects. These data demonstrated that PI3K, and NF-κB contribute to the intracellular signal transduction of the BM-MSC migration induced by PDGFBB. Our previous report also revealed that SB203580 inhibited PDGFBB-induced migration of BM-MSCs (16). Therefore, it can be inferred that PDGFBB mediates the migration of BM-MSCs toward glioma through multiple signal pathways, including PI3K, p38MAPK and NF-κB, and the interaction among them may be required in this procedure (Fig. 7).
Discussion
In the present study, we provided evidence that VCAM-1 is a key factor in the PDGFBB-induced BM-MSC migration. Furthermore, our data demonstrated that the incubation of PDGFBB at the concentrations of 20, 50 and 100 ng/ml significantly enhanced the expressions of VCAM-1 mRNA and protein on BM-MSCs and inhibitors against PI3K, p38 MAPK and NF-κB significantly inhibited PDGFBB-induced VCAM-1 upregulation. It has been described that BM-MSCs express a variety of surface markers, but lack specific markers. Generally, BM-MSCs were identified by the combination of several markers. In the present study, the isolated cells by passage 3 were positive for CD73, CD90 and CD105, and were negative for CD34, CD45, which was in accordance with the characterization of BM-MSCs (29,30).
Gliomas are the most common malignant tumors of the central nervous system. The typical therapies for gliomas include surgical treatment, postoperative radiotherapy and chemotherapy. Complete resection of glioma lesions is difficult and recurrence often occurs, even after adjuvant treatments of chemo- and radiotherapies, due to their invasive growth characteristics, unclear boundaries between tumor and normal brain tissue and the presence of intracranial metastatic and satellite lesions. Moreover, systemic chemotherapy may be accompanied by serious complications and problems such as lack of efficient local distribution in tumor lesions due to the existence of blood-tumor barrier. Hence, targeted gene therapy has attracted increasing attention. It is highly necessary to find delivery vehicles for targeted gene therapy, which migrate toward gliomas efficiently. Bone marrow contains two major types of stem cells, the hematopoietic and non- hematopoietic BM-MSCs (35). As a type of adult stem cells, BM-MSCs have the characteristics of high plasticity and easy amplification and have become a hotspot in the research of stem cells. Studies have demonstrated that BM-MSCs have the ability to migrate towards gliomas (7–9,27). According to this specific tropism, BM-MSCs have been defined as promising cell vectors of targeted gene therapy against glioma (11,12). Numerous studies have been carried out to utilize BM-MSCs as cellular carriers in the treatment of gliomas. Ryu et al(36) reported that BM-MSCs significantly inhibited glioma after being transfected with interleukin-12. Nakamura et al(8) showed that BM-MSCs transfected with interleukin-2 not only clearly inhibited glioma growth but also prolonged the survival of tumor bearing rats. A previous study also proved that the treatment with interferon-β secreting BM-MSCs could suppress the proliferation of glioma cells and resulted in a significant prolonged survival of glioma-bearing animals (10).
However, the mechanisms related to the migration of BM-MSCs toward gliomas remain unclear. In recent years, it has been proven that the migration of BM-MSCs towards gliomas is the result of interactions among inflammatory mediators produced by tumor cells, hypoxia in glioma microenvironment and receptors expressed on BM-MSCs (37). Glioma cells release a variety of cytokines and chemokines, such as vascular endothelial growth factor (VEGF), PDGFBB, endothelial cell growth factor (EGF), transforming growth factor-β1 (TGF), fibroblast growth factor (FGF), neurotrophin-3 (NT-3), and interleukin-8 (IL-8) (8,17,27,38). Among growth factors, PDGF is one of the strongest chemokines that attract BM-MSCs to migrate (39). PDGF promotes the proliferation of fibroblasts, glial cells, smooth muscle cells, epithelial and endothelial cells. The family of PDGF includes four subunits, A, B, C and D. They form five dimers, termed PDGFAA, PDGFAB, PDGFBB, PDGFCC and PDGFDD (28). The five dimeric PDGF ligands act via the two cell surface tyrosine kinase (RTK) receptors, PDGFRα and PDGFRβ (40). PDGFBB binds to both PDGF receptors and has multiple pathophysiological functions. For instance, PDGFBB stimulates the proliferation of glioma-derived cancer-initiating cells and inhibits their apoptosis (41). The secretion of PDGFBB by C6 and U87 glioma cells was confirmed by the ELISA method in the present study. Tondreau et al(42) reported that PDGFBB stimulated the migration of BM-MSCs. Accordingly, authors have reported that PDGFBB plays an important role in the migration of BM-MSCs induced by C6 glioma cells as well (16). Nevertheless, the downstream molecular mechanisms of PDGFBB-induced BM-MSC migration have yet to be fully elucidated. Understanding the mechanisms in the BM-MSC migration may produce more efficient application of stem cells in the treatments of malignant brain tumors. We hypothesized that PDGFBB might play the role through regulating the adhesion molecules expressed on BM-MSCs.
VCAM-1 is an important adhesion molecule and plays a key role in mediating the adhesion and migration of leukocytes and vascular smooth muscle cells (33,34,43). Engelhardt (18) reported that in vivo integrin α4/VCAM-1 interactions mediated earlier steps of T cell/BBB-interaction such as firm adhesion. Previous evidence showed that VCAM-1 inhibition reduced leukocyte transmigration (19). VCAM-1 was demonstrated to be involved in the adhesion of BM-MSCs to cardiac microvascular endothelium as well (21). According to our previous study, VCAM-1 is also expressed in BM-MSCs and can be upregulated with the stimulation of C6 and U87 cells (20). In the present study, we found that the stimulation of PDGFBB promoted VCAM-1 expression in BM-MSCs in a dose-dependent manner. The expression of VCAM-1 was significantly promoted at the concentrations of 20, 50 and 100 ng/ml; 50 ng/ml displayed the maximum promoting effect and no significant difference was observed between the 0 and 10 ng/ml groups. Integrated with our data, PDGFBB-induced VCAM-1 upregulation may be one of the mechanisms in the tropism of BM-MSCs towards gliomas. We then investigated the signaling pathway involved in this process. We examined whether PI3K, P38 MAPK, MEK, JNK and NF-κB played roles in the regulation of VCAM-1 in the present study. RT-PCR and western blot results revealed that PDGFBB-induced VCAM-1 upregulation could be inhibited by LY294002, SB203589 and BAY11-7082, the blocking antibodies of PI3K, P38 MAPK and NF-κB. Therefore, it is reasonable to infer that the PI3K, p38MAPK and NF-κB pathways are involved in the regulation of VCAM-1 by PDGFBB. Moreover, results of in vitro migration assay demonstrated that the inhibition of the PI3K and NF-κB attenuated the PDGFBB-induced migration of BM-MSCs. Our previous data also demonstrated that the inhibition of p38MAPK attenuated the PDGFBB-induced migration of BM-MSCs (16). Based on these results, we inferred that PDGFBB mediates the migration of BM-MSCs toward glioma through multiple signal pathways including PI3K, p38MAPK and NF-κB. However, owing to the complexity of intracellular signal transduction, the molecular mechanism of this migratory behavior merits further studies.
In summary, our present data demonstrated that PDGFBB significantly enhanced the expression of VCAM-1 mRNA and protein expression on BM-MSCs, which facilitated the migration of BM-MSCs induced by PDGFBB. PI3K, p38 MAPK and NF-κB pathways were involved in the signal transduction of this process. These findings extend the understanding of BM-MSC migrating mechanisms and may aid in improving the efficiency of targeted therapies against gliomas using BM-MSCs as carriers.